Why CAR-T is not used in patients with naïve leukemia

CAR-T is not used in patients with naïve leukemia, mainly because the technique is currently only available in patients with relapsed or refractory leukemia.

CAR-T is a new approach to the treatment of malignant tumors based on the principle of genetically engineering a patient's T cells to allow them to recognize and attack cancer cells. This treatment can effectively remove cancer cells from the body, thus achieving the purpose of treatment.

However, CAR-T is currently only available in patients with relapsed or refractory leukemia.This is because CAR-T therapy requires a large number of T cells and needs to be prepared and processed in the laboratory. For patients with naïve leukemia, more T cells are needed to achieve an effective therapeutic effect due to the large number of cancer cells present in the body.

There are also certain risks and complications associated with CAR-T therapy. For example, adverse reactions such as severe immune reactions, infections, etc., may occur during treatment. Before proceeding with CAR-T therapy, the doctor will conduct a thorough evaluation of the patient and develop a personalized treatment plan on a case-by-case basis.

CAR-T is an emerging treatment with great potential. However, it is currently only indicated for patients with specific types of leukemia and requires treatment under the guidance of a medical professional.